Account Login
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Biovie Inc (NQ: BIVI )

42.09 +4.17 (+11.00%)
Official Closing Price Updated: 6:42 PM EST, Jan 19, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Stories about Biovie Inc

54 Biggest Movers From Friday
Gainers Yield10 Bioscience, Inc. (NASDAQ: YTEN) shares jumped 76.9% to close at $13.71 on Friday. ObsEva SA (NASDAQ: OBSV) ... 
Tags PRGS SRNE Market News
From Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers ObsEva (NASDAQ:OBSV) shares rose 57.51% to $3.97 during Friday's regular session. ObsEva's stock is ... 
Tags CRDF LXRX Benzinga
From Benzinga
35 Stocks Moving In Friday's Mid-Day Session
Gainers Ceragon Networks Ltd. (NASDAQ: CRNT) shares surged 54.6% to $4.8699. Ceragon Networks is expected to release its Q4 ... 
Tags Health Care PRGS Market News
From Benzinga
Why Novartis, BioVie, Esperion And VBI Are Moving Today
Esperion Therapeutics (NASDAQ: ESPR) shares are trading lower after Bank of America Securities downgraded the stock from Buy to Neutral ... 
Tags News Penny Stocks Benzinga
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 15, 2021
Upgrades For Stifel Financial Corp (NYSE:SF), Wells Fargo upgraded the previous rating of Underweight to Equal-Weight. ... 
Tags MGLN PINC Downgrades
From Benzinga
77 Biggest Movers From Yesterday
Gainers Synthetic Biologics, Inc. (NYSE: SYN) shares climbed 100% to close at $1.00 on Tuesday after gaining over 30% on ... 
Tags MARA QS ALRN
From Benzinga
70 Biggest Movers From Yesterday
Gainers Arvinas, Inc. (NASDAQ: ARVN) shares climbed 95.1% to close at $58.38 on Monday after the company reported ... 
Tags PRTA GRAY News
From Benzinga
Tuesday 10/20 Insider Buying Report: ARRY, BIVI
As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys. 
Tags Stocks
From Market News Video
62 Biggest Movers From Friday
Gainers COMPASS Pathways Plc (NASDAQ: CMPS) shares jumped 70.6% to close at $29.00 on Friday after pricing its IPO at $17 per ... 
Tags UBX CLRO Market News
From Benzinga
Mid-Afternoon Market Update: Dow Tumbles 300 Points; COMPASS Pathways Shares Spike Higher
Toward the end of trading Friday, the Dow traded down 1.11% to 27591.20 while the NASDAQ fell 1.68% to 10,727.08. The S&P also fell, ... 
Tags ADMP Mid/Afternoon Market Update BIVI
From Benzinga
42 Stocks Moving In Friday's Mid-Day Session
Gainers Cassava Sciences, Inc. (NASDAQ: SAVA) shares jumped 34.6% to $9.54 following news of two insiders buying stock Thursday ... 
Tags IMMP Top Gainers RENN
From Benzinga
Mid-Day Market Update: Nasdaq Turns Lower; Westport Fuel Systems Shares Surge
Midway through trading Friday, the Dow traded down 0.11% to 27872.20 while the NASDAQ fell 0.58% to 10,847.47. The S&P also ... 
Tags BIVI OCN ADMP
From Benzinga
Mid-Morning Market Update: Markets Mixed; US Consumer Sentiment Rises In September
Following the market opening Friday, the Dow traded down 0.18% to 27850.97 while the NASDAQ rose 0.18% to 10,930.12. The S&P also ... 
Tags UCL RKDA BIVI
From Benzinga
IPO Outlook For The Week: Biotech, Banking and Chinese Fintech
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud. The IPO dates below are expected but not ... 
Tags Market News BIVI Benzinga
From Benzinga
BioVie IPO: What You Need To Know
A biotech company that has a mid-stage asset targeting a disease, and currently has no FDA-approved therapies, is eyeing a Nasdaq ... 
Tags BIVI Market News Biotech
From Benzinga
IPO Outlook For The Week: Beauty Treatments, Banking and Liver Therapy
Our latest on AMTD International Inc., Biovie Inc., and Inmode Ltd. 
Tags Financial Pharma/Biotech Healthcare
From Blogs - TalkMarkets
BRIEF-BioVie says first patient dosed in trial for refractory ascites due to liver cirrhosis
* BioVie announces first patient dosed with BIV201 in Phase 2A clinical trial for refractory ascites due to liver cirrhosis Source text for Eikon: Further company coverage: 
Tags companyNews
From Reuters: Company News
BRIEF-Biovie receives FDA clearance for Phase 2A clinic trial in refractory ascites patients
* Biovie receives FDA clearance of IND application for phase 2a clinical trial in refractory ascites patients Source text for Eikon: Further company coverage: 
Tags companyNews
From Reuters: Company News
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.